Where does Bicara Therapeutics's income statement data come from?

Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Research and development	——	——	$33M+33.1%	$24.8M-27.7%	$34.3M+72.4%
General and administrative	$12.74M+56.7%	$8.13M+5.6%	$7.7M+6.7%	$7.22M-3.2%	$7.46M+10.4%
Compensation and benefits	$5.86M+31.7%	$4.45M—	——	——	$3.45M+8.5%
Occupancy and equipment	——	——	——	$500K—	——
Depreciation and amortization	$44K+2.3%	$43K—	——	——	$19K+26.7%
Impairment charges	——	$0—	$0—	$0—	$0—
Other operating expenses	6,024,200,000%-9,536,200,000%	15,560,400,000%+11,492,800,000%	4,067,600,000%+865,800,000%	3,201,800,000%-977,000,000%	4,178,800,000%-4,060,100,000%
Total operating expenses	$60.24M+46.5%	$41.12M+1.1%	$40.68M+27.0%	$32.02M-23.4%	$41.79M+56.9%
Operating income	-$60.24M-46.5%	-$41.12M-1.1%	-$40.68M-27.0%	-$32.02M+23.4%	-$41.79M-56.9%
Interest income	$4.08M+7.8%	$3.79M-13.6%	$4.39M-6.3%	$4.68M-6.6%	$5.01M-14.5%
Other income (expense), net	$4.08M+7.8%	$3.79M-13.6%	$4.39M-6.3%	$4.68M-6.6%	$5.01M-14.5%
Income before income taxes	-$56.16M-50.4%	-$37.33M-2.9%	-$36.29M-32.8%	-$27.34M+25.7%	-$36.77M-77.0%
Income tax expense	$52K-1.9%	$53K+32.5%	$40K-23.1%	$52K-27.8%	$72K-61.3%
Net income	-$56.21M-50.4%	-$37.39M-2.9%	-$36.33M-32.6%	-$27.39M+25.7%	-$36.85M-75.8%
Diluted earnings per share	-$0.93-36.8%	-$0.68-1.5%	-$0.67-34.0%	-$0.50+26.5%	-$0.68—
Basic earnings per share	-$0.93-36.8%	-$0.68-1.5%	-$0.67-34.0%	-$0.50+26.5%	-$0.68—
Weighted-average shares, diluted	60.7M+11.0%	54.7M+0.2%	54.6M0.0%	54.5M+0.2%	54.5M+224%
Weighted-average shares, basic	60.7M+11.0%	54.7M+0.2%	54.6M0.0%	54.5M+0.2%	54.5M+224%
Accretion (Amortization) of Discounts and Premiums, Investments	-$338K-25.7%	-$269K—	——	——	$0—
Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1	——	$0—	$0—	$0—	$0—
Share-based compensation expense related to employee stock plans	$5.86M+31.7%	$4.45M+23.1%	$3.61M+3.5%	$3.49M+1.2%	$3.45M+8.5%
Pre-tax stock-based compensation cost	$5.86M+31.7%	$4.45M+23.1%	$3.61M+3.5%	$3.49M+1.2%	$3.45M+8.5%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	8.3M—	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	$226.78M+402%	-$74.99M—	——	——	-$27.65M-143%
Voting rights, votes per share	——	0.30.0%	0.30.0%	0.30.0%	0.3—
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$56.7M-53.2%	-$37.01M-1.5%	-$36.47M-33.1%	-$27.39M+25.7%	-$36.85M-75.8%
Federal	——	$0—	$0—	$0—	$0—
Current State And Local Tax Expense Benefit	——	$54.25K0.0%	$54.25K0.0%	$54.25K0.0%	$54.25K+16.0%
Federal	——	$0—	$0—	$0—	$0—
Deferred taxes	——	$0—	$0—	$0—	$0—
State	——	$0—	$0—	$0—	$0—
Defined Contribution Plan Cost Recognized	$200K+100%	$100K0.0%	$100K0.0%	$100K0.0%	$100K0.0%
Depreciation	$44K+2.3%	$43K+79.2%	$24K+26.3%	$19K0.0%	$19K+26.7%
Effective tax rates	——	-$00.0%	-$00.0%	-$00.0%	-$0—
Income taxes at U.S. statutory rate of 21%	——	21%—	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	-22.9%—	——	——	——
Other	——	-$00.0%	-$00.0%	-$00.0%	-$0—
Share-based compensation	——	-0.5%—	——	——	——
Permanent differences	——	——	——	——	——
State income taxes – net of federal income tax benefit	——	-0.1%—	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	-2.5%—	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	$7.87M0.0%	$7.87M0.0%	$7.87M0.0%	$7.87M—
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	-$7.23M0.0%	-$7.23M0.0%	-$7.23M0.0%	-$7.23M—
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	——	$14.75K0.0%	$14.75K0.0%	$14.75K0.0%	$14.75K—
Share-based compensation	——	$178K0.0%	$178K0.0%	$178K0.0%	$178K—
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	$23.75K0.0%	$23.75K0.0%	$23.75K0.0%	$23.75K—
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	$41.25K0.0%	$41.25K0.0%	$41.25K0.0%	$41.25K—
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	$844.25K0.0%	$844.25K0.0%	$844.25K0.0%	$844.25K—
Income taxes paid	$0—	——	$167K+221%	$52K-27.8%	$72K—
Short- and long-term operating lease liabilities	-$270K+7.5%	-$292K+7.9%	-$317K-80.1%	-$176K-19.7%	-$147K-150%
Increase (Decrease) in Prepaid Expense and Other Assets	-$2.09M-149%	-$839K—	$0+100%	-$627K+84.8%	-$4.12M-125%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$163.35M+423%	$31.23M+7,063%	$436K+223%	$135K-70.7%	$460K-99.4%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	$100.94M+223%	-$82.33M+65.1%	-$236.12M—	$0—	$0+100%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$37.51M-57.0%	-$23.89M+18.3%	-$29.25M-14.3%	-$25.59M+8.9%	-$28.11M+6.4%
Number of operating segments	1+300%	0.30.0%	0.30.0%	0.30.0%	0.3—
Number of reportable segments	1+300%	0.30.0%	0.30.0%	0.30.0%	0.3—
Offering costs included in accounts payable and accrued expenses	$190K—	——	——	——	$0—
Occupancy and Related Charges	——	——	——	$500K—	——
Operating lease right-of-use assets amortization expense	$273K—	——	$249K+18.0%	$211K+52.9%	$138K—
Non-cash lease expense	——	$223.75K0.0%	$223.75K0.0%	$223.75K0.0%	$223.75K+1,262%
Net unrealized debt securities gains (losses), net of tax	-$486K-228%	$379K+379%	-$136K—	$0—	$0—
Unrealized gains (losses) on available-for-sale securities	-$486K—	——	-$136K—	——	——
Other comprehensive income/(loss)	-$486K-228%	$379K+379%	-$136K—	$0—	$0—
Payments to Acquire Property, Plant, and Equipment	$60K-74.8%	$238K+467%	$42K—	$0—	$0-100%
Proceeds From Issuance Initial Public Offering	——	——	——	——	——
Proceeds from Issuance of Common Stock	$161.76M+448%	$29.5M—	——	——	$0-100%
Proceeds from disposition of marketable securities and other investments	$101M—	——	——	——	$0—
Cash received from option exercises	$1.58M-8.7%	$1.73M+297%	$436K+223%	$135K-70.7%	$460K+497%
Stock-based compensation	$5.86M+31.7%	$4.45M+23.1%	$3.61M+3.5%	$3.49M+1.2%	$3.45M+8.5%
Weighted-average grant date fair value of stock options (in dollars per share)	$13.15-8.7%	$14.40—	——	——	$9.60+28.7%
Granted (in shares)	2.4M-6.7%	2.6M—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	0-100%	190.8K—	——	——	——
Risk-free rate	——	——	——	——	——
Expected dividend rate	$0—	$0—	$0—	——	$0—
Weighted-average volatility	——	——	——	——	——
Intrinsic value of stock options exercised	$5.1M—	——	——	——	$600K+100%
Options canceled (in dollars per share)	$0.00-100%	$8.22—	——	——	——
Granted (in shares)	$16.79+16.6%	$14.40—	——	——	——
Exercised (in shares)	$4.34-12.9%	$4.98—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	366.4K-34.2%	556.7K—	——	——	——
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	$161.76M+2,094%	$7.37M0.0%	$7.37M0.0%	$7.37M0.0%	$7.37M—
Stock Issued During Period, Value, Stock Options Exercised	$1.58M-8.7%	$1.73M+297%	$436K+223%	$135K-71.7%	$477K+397%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	——	$9.7M0.0%	$9.7M0.0%	$9.7M0.0%	$9.7M—
Vesting of early exercise stock options	$0—	——	——	——	$17K0.0%
EBIT	-$60.24M-46.5%	-$41.12M-1.1%	-$40.68M-27.0%	-$32.02M+23.4%	-$41.79M-56.9%
EBITDA	-$60.2M-46.5%	-$41.08M-1.1%	-$40.65M-27.0%	-$32M+23.4%	-$41.77M-56.9%
EBITDA	-$60.2M-46.5%	-$41.08M-1.1%	-$40.65M-27.0%	-$32M+23.4%	-$41.77M-56.9%
EBIT	-$60.24M-46.5%	-$41.12M-1.1%	-$40.68M-27.0%	-$32.02M+23.4%	-$41.79M-56.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Bicara Therapeutics's income statement data come from?: Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.